Paratek Pharmaceuticals, based in Boston, MA, is a biopharmaceutical company dedicated to addressing the critical global public health issue of antimicrobial resistance (AMR). With a focus on developing innovative treatment options for complex medical issues, Paratek is committed to combatting AMR through responsible antibiotic use, improved surveillance, and research into new antibiotics.
Grounded in a mission to save lives, Paratek's FDA-approved tetracycline-class antibiotic, NUZYRA, targets adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria. The company's disciplined team of experts is driven to provide new technologies that can defeat superbugs and contribute to a vibrant marketplace that recognizes the life-saving value of novel antibiotics.
Generated from the website